$8.710
-0.657 (-7.54%)終値時点
ABSI のニュース
ABSI のイベント
H&R Block Rises 16.2% After Earnings
Futures are marginally higher in the opening hours of the evening session with S&P e-minis and NASDAQ 100 contracts, both up by about a decimal. The AI trade has been in a bit of a stasis, with the Technology sector once again eclipsed by the relative safety of Utilities and Energy on Tuesday - the top-performing sectors in the benchmark. Communication Services was a big laggard weighed down by shares of Alphabettrading down by about 4% in today's session.Strong post-earnings results from Super Microand CoreWeaveafterhours could help re-bolster confidence in the tech arena, particularly as markets prepare for the quarterly update from Ciscoovernight - where earnings last time drove a double-digit gap in shares the following day. Before that report however, investors will have a chance to react to a key macro input - monthly CPI inflation data due out Wednesday morning. Recall that core annualized CPI for June reported last month at 2.6% was a three-month low, that month was also marked by a sharp retreat of the geopolitical premium in the oil markets, which had then reversed course in July as US-Iran tensions reignited.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -H&R Blockup 16.2%CoreWeaveup 13.8%CAVA Groupup 12.7%Super Micro Computerup 6.4%Lumentumup 1.1%DOWN AFTER EARNINGS -United States Antimonydown 11.4%Abscidown 10.8%ALSO LOWER -Savers Value Villagedown 13.1% after equity offering
Absci Reports Q2 Revenue of $318,000, Below Consensus
Reports Q2 revenue $318,000, consensus $931,670. "The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next," said Sean McClain, Founder and CEO. "We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027. These results have the potential to demonstrate ABS-201's regenerative mechanism and change the treatment paradigm for the millions of people living with pattern hair loss. And this is just the beginning for our prolactin receptor franchise within our overall proprietary pipeline, with endometriosis expansion ahead."
Major Averages Mixed as Tech Stocks Face Pressure
The major averages had a mixed finish as markets tried to rebound from the sharp technology-led selloff over the prior two sessions. Semiconductor stocks have been at the center of the pressure, with investors reassessing valuations after an extended run higher. Meanwhile, oil prices continue to drop amid optimism over developments in the Middle East.Investors are closely watching earnings from memory-chip maker Micron, which could become an important read-through for broader AI infrastructure spending. Recent weakness in chip shares has revived concerns about whether massive spending on AI data centers and hardware can continue at the same pace.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AlphabetwasVerizonin the Dow Jones Industrial Average as of the open on June 29FedExreportedand provided guidance for 2026Cerebras Systemsreportedand provided guidance for Q2 and FY26President Trump stated in athat customers are being "gouged" by "big oil companies," and ordered the DOJ to investigate the matterThePfizer'sIbrance combo for metastatic breast cancer2. WALL STREET CALLS:BlackBerrywith a Buy at StifelVaronisto Overweight at Stephens on improving growthTake-Twowith a Buy at BTIGPrincipal Financialto Underperform at BofATwiliowith a Buy at Goldman Sachs3. AROUND THE WEB:Paramount Skydanceis preparing for the California and New York attorneys general to sue to block its proposed takeover of Warner Bros. Discovery, NY Post reportsThe Trump administration is urging Metato voluntarily submit its AI models for government review to assess capabilities and risks, NY Times saysTencentis negotiating exits from several game studio investments in Japan as part of a reassessment of the company's global portfolio, Bloomberg reportsQualcommis in discussions to provide its chip-design services to ByteDance, Reuters reportsOn China's black market, Nvidia'sAI chips have doubled in price as the U.S. crackdown on illicit exports coincides with strong demand from Chinese companies, FT says4. MOVERS:Wendy'sjumped as the stockfrom online trading communities as a potential short-squeeze candidateSunrungained afterwith Renew Home and Teslato deliver more than 16 gigawatts of energy capacity to hyperscalers and utilitiesAbsciwas higher afterfrom its human trial of ABS-201Toyowas lower in New York after announcingHertzfell after filing toand announcing plans to offer $300M in aggregate principal amount of Exchangeable Senior First-Lien Secured PIK Notes5. EARNINGS/GUIDANCE:LiveOneand raised its guidance for FY27Paychex, with CEO John Gibson commenting that the company "finished fiscal 2026 with strong momentum"Daktronics, with EPS and revenue beating consensusMoneyHero, with EPS lower year-over-yearKB Homeand provided guidance for Q3 and FY26INDEXES:The Dow rose 182.06, or 0.35%, to 51,848.90, the Nasdaq lost 110.41, or 0.43%, to 25,476.64, and the S&P 500 declined 7.24, or 0.098%, to 7,358.22.
Markets Rebound, Nasdaq Up 0.75%
The major averages were broadly higher as markets rebound from recent losses after a sharp technology-led selloff rattled investors over the last two sessions. Semiconductor stocks have been at the center of the pressure, with investors reassessing valuations after an extended run higher. Meanwhile, oil prices continue to drop amid optimism over developments in the Middle East.Investors are closely watching earnings from memory-chip maker Micron, which could become an important read-through for broader AI infrastructure spending. Recent weakness in chip shares has revived concerns about whether massive spending on AI data centers and hardware can continue at the same pace.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AlphabetwasVerizonin the Dow Jones Industrial Average as of the open on June 29FedExreportedand provided guidance for 2026Cerebras Systemsreportedand provided guidance for Q2 and FY26President Trump stated in athat customers are being "gouged" by "big oil companies," and ordered the DOJ to investigate the matterFuelCelland Fit Energy announced afor up to 380 megawatts of clean, baseload on-site power for data centers2. WALL STREET CALLS:BlackBerrywith a Buy at StifelVaronisto Overweight at Stephens on improving growthTake-Twowith a Buy at BTIGPrincipal Financialto Underperform at BofATwiliowith a Buy at Goldman Sachs3. AROUND THE WEB:The Trump administration is urging Metato voluntarily submit its AI models for government review to assess capabilities and risks, NY Times saysTencentis negotiating exits from several game studio investments in Japan as part of a reassessment of the company's global portfolio, Bloomberg reportsEli Lillywill be using its cash pile to fund untested drug development strategies in preparation for the expiration of patents on its weight-loss drugs, FT saysQualcommis in discussions to provide its chip-design services to ByteDance, Reuters reportsOn China's black market, Nvidia'sAI chips have doubled in price as the U.S. crackdown on illicit exports coincides with strong demand from Chinese companies, FT says4. MOVERS:Wendy'sjumps as the stock attracted attention from online trading communities as a potential short-squeeze candidateSunrungains afterwith Renew Home and Tesla (TSLA) to deliver more than 16 gigawatts of energy capacity to hyperscalers and utilitiesAbscihigher afterfrom its human trial of ABS-201Toyolower in New York after announcing aHertzfalls after$100M of common stock and announcing plans to offer $300M in aggregate principal amount of Exchangeable Senior First-Lien Secured PIK Notes5. EARNINGS/GUIDANCE:LiveOneand raised its guidance for FY27Paychex, with CEO John Gibson commenting that the company "finished fiscal 2026 with strong momentum"Daktronics, with EPS and revenue beating consensusMoneyHero, with EPS lower year-over-yearKB Homeand provided guidance for Q3 and FY26INDEXES:Near midday, the Dow was up 0.95%, or 490.51, to 52,157.35, the Nasdaq was up 0.75%, or 193.06, to 25,780.10, and the S&P 500 was up 0.65%, or 48.24, to 7,413.70.
Absci Reports Positive Phase 1 Data for ABS-201
Absci reported positive interim Phase 1 data from its first-in-human trial of ABS-201, an investigational anti-prolactin receptor, or PRLR, antibody. The ABS-201 Phase 1 trial is an ongoing, first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and pharmacokinetics, or PK, of ABS-201 in healthy volunteers with and without androgenetic alopecia, or AGA. These data comprise 32 healthy adult participants enrolled into four planned single ascending dose, or SAD, cohorts. Dose levels evaluated were 150 mg, 450 mg, 900 mg and 1800 mg administered intravenously, or IV. Interim blinded safety data from these cohorts as of the June 8, 2026 data cutoff are summarized below. Following review of blinded SAD safety and PK data by the trial's Safety Review Committee, the study has advanced into the subcutaneous multiple ascending dose, or MAD, portion in participants with AGA. Safety: Blinded, aggregate interim data suggest study drug was well tolerated and exhibited a favorable safety and tolerability profile. No serious adverse events were reported as of the data cutoff date. All treatment-emergent adverse events were mild in severity except for a single moderate TEAE in SAD cohort 3, which was assessed as unlikely related to study treatment. Treatment-related TEAEs were reported in 5 participants and were all mild. The most frequently reported TEAE across cohorts was headache. Immunogenicity: No apparent impact of anti-drug antibodies, or ADAs, on PK was observed based on interim data in the SAD cohorts. ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in in vivo studies. In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in a preclinical mouse model. Absci anticipates interim proof-of-concept data from its ongoing HEADLINE study in the second half of 2026, with full proof-of-concept data in early 2027.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。